|
|
Algel-IMDQ |
|
Vaxjo ID |
235 |
|
Vaccine Adjuvant Name |
Algel-IMDQ |
|
Adjuvant VO ID |
VO_0005722
|
|
Description |
Algel-IMDG is a combination of aluminum hydroxide gel (Algel) and a TLR7/8 agonist (imidazoquinoline class) that promotes Th1 immune responses |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel) |
|
Structure |
Physicochemical composition includes aluminum gel adsorbed with imidazoquinoline, a small molecule TLR7/8 agonist |
|
Appearance |
Sterile liquid suspension, identical in appearance, color, and viscosity across formulations |
|
Storage |
Stored at 2–8°C, compatible with standard vaccine cold chain |
|
Preparation |
Preformulated by manufacturer; ready-to-use vials containing Algel-IMDG and antigen (no reconstitution needed) |
|
Dosage |
Preformulated by manufacturer; ready-to-use vials containing Algel-IMDG and antigen (no reconstitution needed) |
|
Function |
It is a stable adjuvant. It appears overall safe since it has been used in the licensed COVAXIN vaccine against COVID-19. |
|
Safety |
Generally well tolerated; no vaccine-related serious adverse events |
| References |
Ella et al., 2021: Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet. Infectious diseases. 2021; 21(5); 637-646. [PubMed: 33485468].
|
|
